Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced...

Area of Science:

• Oncology
• Muscle Physiology
• Immunology

Background:

• Skeletal muscle wasting (cancer cachexia) is prevalent in advanced cancer, leading to poor prognosis.
• Myostatin, a negative regulator of muscle mass, is a potential therapeutic target for muscle loss.
• Cancer-induced muscle wasting significantly reduces patient survival and quality of life.

Purpose of the Study:

• To evaluate neutralizing antimyostatin antibodies as a therapeutic strategy against cancer-induced skeletal muscle wasting.
• To assess the efficacy of these antibodies in preclinical cancer models.
• To determine if antibody efficacy is affected by chemotherapy or caloric restriction.

Main Methods:

• Generation of neutralizing antibodies against myostatin.
• Administration of antibodies to non-tumor-bearing mice to assess effects on muscle mass and strength.
• Testing antibodies in preclinical models of cancer-induced muscle wasting (C26 colon and PC3 prostate carcinoma).
• Evaluating antibody effects in combination with gemcitabine chemotherapy and during caloric restriction.

Main Results:

• Antimyostatin antibodies significantly increased body weight, skeletal muscle mass, and strength in healthy mice.
• Antibodies attenuated muscle mass and strength loss in preclinical cancer models without affecting tumor growth.
• The muscle-preserving effects were maintained when antibodies were coadministered with gemcitabine.
• Antibody treatment preserved skeletal muscle mass during caloric restriction.

Conclusions:

• Neutralizing antimyostatin antibodies are effective in preventing and treating cancer-induced skeletal muscle wasting.
• These antibodies represent a promising therapeutic approach for cachexia in cancer patients.
• The therapeutic benefits are independent of tumor growth and chemotherapy interactions.